Monoclonal therapeutic antibodies have revolutionized the treatment of cancer and other
diseases. Fc engineering aims to enhance the effector functions or half-life of therapeutic …

Multiple myeloma (MM) is a currently incurable hematologic cancer. This disease is
characterized by immunological alterations of myeloid cells and lymphocytes. The first-line …

Although many patients with diffuse large B cell lymphoma (DLBCL) may achieve a
complete response to frontline chemoimmunotherapy, patients with relapsed/refractory …

Abstract The 2022 16th Workshop on Recent Issues in Bioanalysis (WRIB) took place in
Atlanta, GA, USA on September 26–30, 2022. Over 1000 professionals representing …

Although immune checkpoint blockade therapies have shown evidence of clinical
effectiveness in many types of cancer, the outcome of clinical trials shows that very few …

Uveal melanoma (UM), the primary intraocular tumor in adults, arises from eye melanocytes
and poses a significant threat to vision and health. Despite its rarity, UM is concerning due to …

In relapsed and refractory multiple myeloma (RRMM), there are few treatment options once
patients progress from the established standard of care. Several bispecific T-cell engagers …

T cell–retargeting therapies have transformed the therapeutic landscape for hematologic
diseases. T cell–dependent bispecific antibodies (TDB) function as conditional agonists that …

Simple Summary Since the identification of a large variety of biomarkers in B cell
malignancies as being driving factors for tumor progression and patient prognosis, their …

Quantitative systems pharmacology (QSP) models are an important facet of pharmaceutical
and clinical research as they combine mechanistic models of physiology in health and …